Trending stocks today
Roivant (ROIV-Q)
NASDAQ:ROIV
11.03
0.10
(0.90%) 1d
Financials
Technical Analysis
Buy, Sell or Hold?
This summary was created by AI, based on 1 opinions in the last 12 months.
Roivant, with symbol ROIV-Q, has recently received positive results for its new product targeting eye inflammation and pain, showing potential for significant growth. The company is trading at a low valuation with strong cash reserves and a $1.2 billion share buyback plan. Its recent revenue beat expectations and is expected to grow consistently for the next five years. Analysts recommend setting a stop-loss at $7.50 and aiming for $16.00.
$10.920
Unknown
- «
- ‹
- 1
- ›
- »
Roivant(ROIV-Q) Rating
Ranking : 1 out of 5
Bullish - Buy Signals / Votes : 0
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 0
Total Signals / Votes : 0
Roivant(ROIV-Q) Frequently Asked Questions
What is Roivant stock symbol?
Roivant is a American stock, trading under the symbol ROIV-Q on the NASDAQ (ROIV). It is usually referred to as NASDAQ:ROIV or ROIV-Q
Is Roivant a buy or a sell?
In the last year, there was no coverage of Roivant published on Stockchase.
Is Roivant a good investment or a top pick?
Roivant was recommended as a Top Pick by on . Read the latest stock experts ratings for Roivant.
Why is Roivant stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Roivant worth watching?
0 stock analysts on Stockchase covered Roivant In the last year. It is a trending stock that is worth watching.
What is Roivant stock price?
On 2024-04-30, Roivant (ROIV-Q) stock closed at a price of $11.03.
The pharma company recently received supportive results for its new product which helps bring relief to patients with eye inflammation and pain and can help avoid total blindness -- steroids are presently the primarily treatment currently. It trades at 2x trailing earnings and 1.4x book value. The board has approved a $1.2 billion share buyback, which it has ample and growing cash reserves to manage. Recently reported revenues beat expectations, growing by 118% from the year previous and is expected to grow by 50% p.a. for at least the next five years. We recommend setting a stop-loss at $7.50, looking to achieve $16.00. Yield 0%
(Analysts’ price target is $16.08)